Pfizer’s disclosure last week that it may reverse plans to in-shore manufacturing facilities and science jobs to the United States is just the tip of the iceberg of the problems we’ll face if President Trump implements his executive order to implement foreign reference pricing to determine drug prices under Medicare.
{iframe}https://thehill.com/blogs/congress-blog/healthcare/510325-trump-order-threatens-small-biotechs-driving-covid-innovation{/iframe}